Core Insights - Microsoft has expanded its data center footprint to over 400 sites in 70 regions and introduced a sovereign cloud offering, expecting to spend $30 billion in capital expenditures in Q1 to meet AI infrastructure demand [1][8][14] - Azure revenue reached a record $75 billion for the year, with a 34% increase in annual revenue, driven by demand for cloud and AI services [2][4][5] Financial Performance - Microsoft reported higher-than-expected revenue and earnings growth in its fiscal fourth quarter, with net income of $27.2 billion, or $3.65 per share, a 24% increase year-over-year [9][10] - Total revenue for the fiscal year was $281.7 billion, up 15%, with net income of $101.8 billion and earnings per share of $13.64, a 16% increase [14] Business Unit Growth - Nearly all business units experienced double-digit percentage growth, with productivity and business processes revenue rising 16% to $33.1 billion [4][12] - Microsoft 365 Commercial cloud revenue increased by 18%, and the company added a record number of new Copilot customers during the quarter [12] Cloud and AI Services - Microsoft's cloud revenues, including Azure and other services, totaled $168 billion for the year, up 23% year-over-year [5] - Azure AI remains a key priority, with 57% of CIOs expecting to use Azure OpenAI Services and 31% planning to use GitHub Copilot in the next 12 months [7] Market Position and Future Outlook - Morgan Stanley analysts predict continued robust growth for Azure, with 52% of CIOs indicating their application workloads are in Azure [6] - Microsoft expects continued double-digit growth in revenue and operating income in fiscal 2026, supported by strong demand for cloud and AI [14]

Core Insights - Akeso, Inc. has initiated a pivotal Phase III clinical study for ivonescimab, a PD-1/VEGF bispecific antibody, in combination with docetaxel for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after PD-1/L1 inhibitors and platinum-based chemotherapy [1][4] - Ivonescimab is currently the only bispecific immunotherapy antibody in Phase III trials for IO-resistant lung cancer, highlighting its unique position in the market [2] - The study aims to address the significant unmet need in treating IO-resistant NSCLC, as current options are limited and docetaxel's efficacy as a monotherapy is restricted [4][6] Industry Context - Immunotherapy has made substantial advancements in NSCLC treatment, with PD-1/L1 inhibitors becoming standard first-line therapies; however, 60%-70% of patients still experience disease progression within the first year [3] - There are no approved standard treatment options for IO-resistant NSCLC, making the development of ivonescimab particularly relevant [4] - Mechanistic studies indicate that combining PD-1 and anti-VEGF therapies may yield synergistic effects, enhancing anti-tumor immune responses and potentially improving treatment outcomes for IO-resistant tumors [5][6] Company Overview - Akeso is a leading biopharmaceutical company focused on developing innovative biological medicines, with a robust pipeline of over 50 assets across various disease areas, including cancer [11] - The company employs a unique integrated R&D innovation system and has developed a comprehensive drug development platform, positioning itself competitively in the global biopharmaceutical market [11] - Akeso's commitment to creating first-in-class and best-in-class drugs aims to provide affordable therapeutic options for patients worldwide, contributing to its goal of becoming a global leader in the biopharmaceutical industry [11]

Trench warriors on @katana, rise up 🔼@kenseionkatana is live.Grad tokens coming soon to Sushi 🍣Stay tuned.KENSEI (@kenseionkatana):⚔️ The Wait Is Over. Kensei Beta Has Arrived. ⚔️The first and only meme launchpad on @katana is now LIVE.Here’s what we’re bringing to the memecoin realm ⬇️ https://t.co/6IxeXNGNMP ...

消息面上，石药集团宣布，已与Madrigal Pharmaceuticals,Inc.(Madrigal)就集团的口服小分子激活胰高血 糖素样肽-1(GLP-1)受体激动剂SYH2086在全球的开发、生产及商业化订立独家授权协议。根据协议条 款，集团同意授予Madrigal在全球范围内开发、生产及商业化SYH2086的独家授权，同时保留集团在中 国开发和销售其他口服小分子GLP-1受体激动剂产品的权益。集团有权收取最高可达20.75亿美元的总代 价，包括1.2亿美元的预付款、最高可达19.55亿美元的潜在开发、监管及商业里程碑付款，以及基于 SYH2086年度净销售额的高达双位数销售提成。 智通财经APP获悉，石药集团(01093)涨超5%，截至发稿，涨5.15%，报10.62港元，成交额6.08亿港元。 ...

格隆汇7月31日｜Meta Platforms(META.O)第二季度营收超过预期，对当前时期的预测也强于预期，这 表明这家社交媒体公司的广告业务仍在快速增长，足以支持其在人工智能方面的大举支出。财报公布 后，Meta美股盘后一度大涨10%。Meta预计，其第三季度营收将达到475亿美元至505亿美元，此外， Meta还上调了2025财年资本开支预期区间的下限，因为该公司继续加大对人才、基础设施、数据中心 和能源的投资，以在快速发展的AI竞赛中保持竞争力。Meta目前预计全年资本支出将在660亿美元至 720亿美元之间，较此前640亿至720亿美元的预期有所提高。 ...

2025.07.31 本 美国国债收益率上升，10年期利率上升5.3个基点至4.38%，2年期利率上涨7.6个基点至3.95%。 根据伦 敦证交所的数据，在美联储发表声明后，市场对9月降息的预期攀升至约68%，但在鲍威尔发表评论 后，这一预期降至50%以下。 Meta、微软业绩好于预期 Meta周三盘后公布业绩，营收475.2亿美元，市场预期448.3亿美元。其中广告营收465亿美元，市场预 期440.7亿美元。Reality Labs部门亏损为45亿美元， 市场预期亏损48亿美元。每股收益EPS 7.14美元， 市场预期5.89美元。 文字数：1526，阅读时长大约3分钟 作者 | 第一财经 樊志菁 周三美股涨跌互现， 美国二季度GDP好于预期，投资者关注美联储决议和大型科技股财报。 截至收盘，道指下跌0.38%，至44461.28点，纳指上涨0.15%，收于21129.67点，而标普500指数下跌 0.12%，收于6362.90点。 美联储公布利率决议，维持联邦基金利率不变，符合市场预期。美联储主席鲍威尔表示，9月是否降息 尚未作出决定，美联储需要确保关税因素不会从一次性的价格上涨变成真正的持续通胀问题。 ...

祁玉蓉（F03100031, Z0021060），联系电话：010-8229 5006 | 铅锌日评20250731：区间整理 | | | | | | --- | --- | --- | --- | --- | | 2025/7/31 指标 单位 | | 今值 变动 近期趋势 | | | | 元/吨 SMM1#铅锭平均价格 | | 16,750.00 -0.15% | | | | 沪铅期现价格 期货主力合约收盘价 元/吨 | | 16,890.00 -0.06% | | | | 沪铅基差 元/吨 | | -140.00 -15.00 | | | | 元/吨 升贴水-上海 | | -25.00 - | | | | 升贴水-LME 0-3 美元/吨 | | -36.37 -4.57 | | | | 升贴水-LME 3-15 美元/吨 | | -65.70 -3.20 | | | | 价差 沪铅近月-沪铅连一 元/吨 | | -20.00 - | | | | 元/吨 沪铅连一-沪铅连二 铅 | | -10.00 5.00 | | | | 沪铅连二-沪铅连三 元/吨 | | -20.00 - | | | | 期货活跃 ...

Activist investor Ancora is a “growing shareholder” in rail operator CSX, at a time when the industry is bracing for further consolidation https://t.co/QsdNK4Pny8 ...

RT MetaMask.eth 🦊 (@MetaMask)Ethereum is celebrating 10 years of building the future.Next year, MetaMask turns 10 too - a decade of supporting Ethereum from the beginning. 🦊The first decade was about building the rails.The next will be about onboarding the world.We’re still early. https://t.co/TZTLB1i8hY ...

凤凰网财经讯 7月31日，三大指数开盘涨跌不一，沪指低开0.30%，深成指高开0.05%，创业板指高开 0.65%。CPO、PCB等板块指数涨幅居前，军工、有色金属等板块指数跌幅居前。 | | | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | *● | 最新 | 涨幅% | | 涨跌 | 涨速% | | 现手 金额 | | 上证指数 | | 3604.70 | -0.30 | -11.02 | 496/1485 | -0.08 | 531万 | 531万 61.38亿 | | 深证成指 | | 11208.46 | 0.05 | 5.43 | 576/1931 | 0.07 | 537万 | 537万 81.28亿 | | 北证50 | | 1437.82 | -0.13 | -1.82 | 113/130 | -0.07 | 12.1万 | 12.1万 2.87 亿 | | 创业板指 | | 2382.97 | 0.65 | 15.29 | 303/924 | 0.31 | 172万 ...